BALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a panel discussion and 1x1 investor meetings at the Citi 18^th Annual BioPharma Conference, taking place in Boston, MA from September 5 - 7, 2023.

Details on the panel discussion can be found below.

Title: Rare Neurological Diseases
Date: Wednesday, September 6, 2023
Time: 8:50 – 9:35 AM ET

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
(484) 414-2715